2-Chloro-N-[3,5-dichloro4-(5-trifluoromethyl-benzothiazol-2-ylsulfanyl)-phenyl]4-trifluoromethyl-benzenesulfonamide | 315225-18-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-Chloro-N-[3,5-dichloro4-(5-trifluoromethyl-benzothiazol-2-ylsulfanyl)-phenyl]4-trifluoromethyl-benzenesulfonamide
• 英文别名: 2-chloro-N-[3,5-dichloro-4-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]sulfanyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide
• CAS: 315225-18-4
• 化学式: C₂₁H₉Cl₃F₆N₂O₂S₃
• 分子量: 637.862
• InChiKey: SQSZETKTIKKSBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  12

文献信息

• Novel 17beta-hydroxysteroid dehydrogenase type I inhibitors
  申请人：Messinger Josef

  公开号：US20050192263A1

  公开（公告）日：2005-09-01

  3,15-substituted estrone compounds which act as inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17β-estradiol concentration, as well as the general use of selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.

  3,15-取代雌二醇化合物，作为17β-羟基类固醇脱氢酶I型（17β-HSD1）的抑制剂，其盐，含有这种化合物的药物制剂，制备这种化合物的方法，以及这种化合物的治疗用途，特别是在治疗或抑制类固醇激素依赖性疾病或紊乱方面，例如需要抑制17β-羟基类固醇脱氢酶I型酶和/或需要降低内源性17β-雌二醇浓度的类固醇激素依赖性疾病或紊乱，以及具有纯拮抗性结合亲和力或仅具有纯拮抗性结合亲和力的选择性17β-羟基类固醇脱氢酶I型抑制剂的一般用途，用于治疗或抑制良性妇科疾病，特别是子宫内膜异位症。
• Therapeutic modulation of PPARgamma activity
  申请人：Chen Jin-Long

  公开号：US20050250820A1

  公开（公告）日：2005-11-10

  Modulators of PPARγ activity are used in methods of treating and/or preventing conditions such as osteoporosis, Alzheimer's disease, psoriasis and acne, and cancer.

  PPARγ活性调节剂被用于治疗和/或预防骨质疏松症、阿尔茨海默病、银屑病和痤疮以及癌症等疾病的方法中。
• Compounds for the modulation of PPARgamma activity
  申请人：Tularik Inc.

  公开号：US20030139390A1

  公开（公告）日：2003-07-24

  Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了调节PPAR&ggr;活性的调节剂，可用于制药组合物和治疗类型II糖尿病和肥胖等疾病的方法。
• Compounds for the modulation of PPARy activity
  申请人：Tularik Inc.

  公开号：US20040248882A1

  公开（公告）日：2004-12-09

  Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了PPAR&ggr;活性调节剂，可用于制备药物组合物和治疗II型糖尿病和肥胖等疾病的方法。
• COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY
  申请人：McGee Lawrence R.

  公开号：US20100113522A1

  公开（公告）日：2010-05-06

  Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

  提供了PPARγ活性调节剂，可用于制备药物组合物和治疗2型糖尿病和肥胖等疾病的方法。